Lundbeck loses €150m pay-for-delay appeal
30-03-2021
Lundbeck and Takeda take on Lupin over anti-depressant ANDA
23-05-2018
Sebastian Duda / Shutterstock.com
The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
EU General Court, European Commission, pay-for-delay, Lundbeck, patent, appeal, citalopram, Merck, Sun Pharma
